Clinical Cohort Study of 21-gene Assay in Predicting the Prognosis of Elder Luminal-A Breast Cancer Patients With Axillary Lymph Node Metastasis

What this Trial Is About

Researchers are investigating elderly female patients aged 65 years and older with Luminal A type breast cancer that has spread to lymph nodes after surgery. This observational study aims to assess whether a 21-gene assay can predict survival outcomes and the benefits of chemotherapy in these patients. The study focuses on clinical and pathological data including imaging, treatment plans, and medication strategies to better understand disease progression and treatment impact. The study collects paraffin tissue samples from both the primary breast cancer and metastatic lymph nodes for a 21-gene assay, which calculates a recurrence risk index. Patients will be followed every 12 months after surgery to monitor for disease recurrence. After recurrence, survival is followed every three months until death. This approach allows researchers to observe real-world treatment effects and outcomes without administering experimental treatments. Participants will have their clinical information and treatment details recorded, including whether chemotherapy, radiotherapy, endocrine therapy, or targeted therapy were used after surgery. Follow-up includes regular assessments and survival tracking until the patient reaches age 80 or passes away. Data collected will help evaluate the predictive value of the 21-gene assay and guide treatment decisions for elderly breast cancer patients with lymph node involvement.

21-gene in Elder Breast Cancer Patients With Lymph Node Metastasis